How Can a Drug Lasting Hours Change the Brain for Months?

Psychedelic medicine reached an important turning point this week. The U.S. Departments of Veterans Affairs and Health and Human Services announced a partnership to accelerate research on psychedelic therapies for military veterans with PTSD, depression, traumatic brain injury, and substance use disorders. At nearly the same time, the FDA finalized its long-awaited guidance for sponsors developing psychedelic medicine, announcing a public hearing on their future therapeutic use. Together with the recent executive order, these actions suggest psychedelic therapies are moving from the scientific margins toward mainstream clinical medicine.

The announcement reminded me of one of the most thought-provoking questions in modern neuroscience: How can a psychedelic drug that lasts only hours change the brain for months?

Although ketamine, psilocybin, LSD, 5-MeO-DMT, and ibogaine act through very different receptor systems, they apparently share an unusual property: their therapeutic benefits persist long after the drugs have disappeared from the body.

For decades, psychiatry accepted that meaningful antidepressant effects required weeks or months of daily treatment. Then ketamine challenged that assumption by producing rapid depression improvements in hours. Soon afterward, carefully conducted studies of psilocybin—and more recently, other psychedelics —reported something equally remarkable. Some patients experienced meaningful improvements lasting weeks or months after a single treatment.

How Does a Drug Lasting Hours Change the Brain for Extended Periods?>

Source: Mark Gold, MD with permission

Ibogaine has posed the same puzzle for decades. From 1996 to 2005, my colleague Dr. Deborah Mash conducted pioneering clinical research and development studies in St. Kitts. There, patients with opioid use disorder often experienced prolonged reductions in withdrawal symptoms and cravings after one ibogaine treatment. At the time, there was no convincing biological explanation for how such brief drug exposure could produce these durable clinical effects.

One clue comes from recent work by Joshua Siegel, M.D., Ph.D., and colleagues. Using advanced functional brain imaging, they demonstrated that psilocybin temporarily interrupts the brain's normally stable patterns of functional connectivity. As those networks recover, the brain appears to reorganize itself rather than simply returning to its previous state.

Similar findings are emerging with other psychedelics. Together, these studies suggest ketamine, psilocybin, LSD, 5-MeO-DMT and ibogaine may be teaching us something fundamental—not simply about consciousness, but about one of the brain's defining properties: its remarkable capacity to change.

Neuroscientists call that capacity neuroplasticity—the brain's ability to learn, adapt, and recover throughout life. The same biological process that makes learning possible can also be hijacked. Addiction may be medicine's clearest example of maladaptive learning.

Repeated drug exposure progressively reshapes the brain's reward circuitry. Drug-associated people, places, emotions, and routines acquire extraordinary motivational value, while natural rewards—family, relationships, work, food, and achievement—gradually lose their influence. Neuroscientists call this incentive salience. Patients often describe it more simply: "Nothing else matters anymore."

Addiction is therefore more than repeated drug use. It is a disorder in which the brain's priorities are gradually rewritten.

This perspective also changes how we think about treatment. Traditional psychopharmacology has focused primarily on neurotransmitters and receptors. Most medications work only while they are being taken. But ketamine, psilocybin, LSD, 5-MeO-DMT, and perhaps ibogaine appear fundamentally different. Their greatest therapeutic effect may not be what they do while present, but what they leave behind after they are gone.

Recent studies increasingly point toward adaptive neuroplasticity as the therapeutic target. Brief receptor activation appears capable of initiating longer-lasting changes in gene expression, synaptic connectivity, dendritic architecture, reward responsiveness, and behavioral flexibility.

The question is no longer simply, "What receptor does this drug activate?" Instead, it is becoming, "What kind of brain does this drug leave behind?"

Psychedelics Essential Reads

Psychedelic Integration Is Reflected in How You Live

LSD Today for a Better Brain Tomorrow

Dopamine was described in the past as the brain's "pleasure chemical." But, today, dopamine is thought to be the brain's principal teaching signal. Dopamine helps determine what deserves attention, predicts future reward, and gradually shapes what the brain learns to pursue.

Addiction is a disorder of maladaptive learning. Repeated drug exposure strengthens reward circuitry that favors drug use over healthier, natural rewards.

Several important papers just published in July 2026 help explain how a drug present in the brain for only a few hours can produce therapeutic benefits that last for weeks or even months.

Christopher W. Thomas and colleagues (McLean Hospital/Harvard Medical School) reported persistent improvements in reward responsiveness following a single psilocybin treatment, providing a potential explanation for the reversal of anhedonia. Jenna Houff and colleagues (University of Mississippi Medical Center) demonstrated sustained activation of parvalbumin inhibitory interneurons associated with perineuronal nets in the medial prefrontal cortex, suggesting a mechanism through which psychedelics may restore cortical plasticity and improve executive control. Chinese Academy of Sciences' Cong Lin and Xiaohui Wang, in the 2026 Molecular Psychiatry review, integrated emerging evidence that psychedelics and ketamine engage epigenetic mechanisms—including DNA methylation, histone modifications, chromatin remodeling, and RNA regulation—that can produce persistent changes in gene expression, dendritic architecture, synaptic connectivity, and neuroplasticity long after the drug has been eliminated.

Taken together, these data suggest that ketamine and psychedelics may do something fundamentally different from typical medications. They appear to transiently reopen a window of neuroplasticity, allowing maladaptive reward learning to be updated and healthier patterns of motivation, decision-making, and behavior to emerge.

Rather than simply suppressing symptoms, these therapies may temporarily restore the brain's capacity to learn and recover. If that proves true, their greatest therapeutic effect may not be during the hours the drug is present, but in the weeks and months afterward, when the brain continues to remodel itself toward healthier, more adaptive patterns of reward and behavior.

Rebooted?

Patients often describe treatment as a "brain reboot." The analogy is imperfect. Rather than resetting the brain, these drugs may temporarily increase its capacity to reorganize itself.

Rigid patterns of maladaptive reward learning thus may become more modifiable, allowing healthier reward circuits to regain influence while natural rewards once again compete successfully with drug-associated cues.

The goal isn’t erasing the past. It’s to reduce the pathological dominance of addiction while restoring the brain's ability to again value people, relationships, purpose, and meaningful experiences.

The FDA's recent guidance reveals this evolution. Rather than asking whether psychedelic therapies deserve rigorous study, the agency is now delivering a roadmap for how research should be administered safely and effectively. That shift reveals the field is moving from scientific possibility toward clinical reality.

Much remains unknown. We still don’t know which patients will benefit most from psychedelic therapies, how durable these effects will prove, or how short-lived molecular events may become lasting behavioral change, and for whom the risk of psychedelics exceeds benefits. These remain among the most important questions in contemporary neuroscience.

One central idea is emerging. Repeated exposure to addictive drugs produces maladaptive neuroplasticity. Ketamine, psilocybin, LSD, 5-MeO-DMT, and ibogaine may briefly create a biological window during which healthier learning can compete with maladaptive reward learning. The question is no longer simply, "What receptor does this drug activate?" Instead, it is becoming, "What kind of brain does this drug leave behind?" Rather than erasing the past, they may restore the brain's capacity to learn and recover.

If that theory proves correct, the lasting therapeutic effects of ketamine, psychedelics, and ibogaine may represent not an exception to neuroscience, but a new model to understand how brief biological interventions can produce enduring changes in learning, reward, and recovery.

Recovery is not about forgetting addiction. It’s about remembering what really matters in life.